Corteva (CTVA) and Hexagon Bio announced a multi-million-dollar joint venture to accelerate the development of new crop protection solutions inspired by nature. The JV is the first in the agriculture sector for Hexagon Bio and the first in the pharmaceutical industry for Corteva. The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA:
- Corteva’s Growth Potential Bolstered by Strategic Collaborations and Legal Developments
- Corteva assumed with an Overweight at Wells Fargo
- Corteva price target raised to $76 from $75 at Oppenheimer
- Corteva’s Strategic Adjustments and Strong Crop Protection Performance Drive Buy Rating
- Corteva’s Strong Q3 Performance Boosts 2025 Outlook